US Smoking Cessation Clinical Trials Guidance ‘Does Not Envision’ Flexibility On Indications
Executive Summary
FDA final guidance maintains limit on secondary endpoints allowed for trials, which could dissuade some investment in research for NDAs for smoking cessation products. NRT developers could find more room for novel product proposals from changes to some phrasing.
You may also be interested in...
House FY2024 FDA Appropriation Bill Cuts Funding
Tobacco rules limiting nicotine and banning menthol in cigarettes also would be defunded in the bill.
House FY 2024 Approps Bill Nixes US FDA Mifepristone REMS Changes, Cuts Funding
Tobacco rules limiting nicotine and banning menthol in cigarettes also would be defunded in the bill.
US FDA Calls For Clinical Trial Diversity Plan ‘As Soon As Practicable’ In Product Development
Draft guidance outlines Race and Diversity Plan that would reify some of FDA’s efforts to increase racial and ethnic diversity in clinical trials with a mechanism that is applicable from IND through approval.